Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Acrivon Therapeutics Inc. (ACRV) Insider Trading Activity

    Healthcare • Biotechnology • 58 employees

    Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

    Total Value

    -$954,218.82

    Total Shares

    -142,928

    Average Trade Value

    -$50,222.04

    Most Active Insider

    Blume Jensen Peter

    Total Activity: $920,218

    Largest Single Transaction

    $473,347

    by Blume Jensen Peter on Nov 14, 2024

    30-Day Activity

    8 Transactions

    Volume: 59,595 shares
    Value: $325,393

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    President and CEO
    Feb 21, 2025 19,904 $110,268 2,285,781 (-0.9%) Payment of Exercise Price
    Chief Accounting Officer
    Feb 14, 2025 116 $629 4,419 (-2.6%) Payment of Exercise Price
    President and CEO
    Feb 14, 2025 579 $3,138 316,177 (-0.2%) Payment of Exercise Price
    President and CEO
    Feb 14, 2025 37,152 $201,364 2,305,685 (-1.6%) Payment of Exercise Price
    Chief Legal Officer
    Feb 14, 2025 217 $1,176 37,065 (-0.6%) Payment of Exercise Price
    Chief Development Officer
    Feb 14, 2025 469 $2,542 16,492 (-2.8%) Payment of Exercise Price
    Chief Financial Officer
    Feb 14, 2025 434 $2,352 26,088 (-1.7%) Payment of Exercise Price
    Chief Operating Officer
    Feb 14, 2025 724 $3,924 67,147 (-1.1%) Payment of Exercise Price
    Chief Legal Officer
    Jan 17, 2025 659 $3,809 37,282 (-1.8%) Payment of Exercise Price
    President and CEO
    Nov 21, 2024 19,910 $128,220 2,342,837 (-0.8%) Payment of Exercise Price
    President and CEO
    Nov 14, 2024 490 $3,881 316,756 (-0.2%) Payment of Exercise Price
    Chief Accounting Officer
    Nov 14, 2024 99 $784 4,535 (-2.2%) Payment of Exercise Price
    Chief Financial Officer
    Nov 14, 2024 368 $2,915 26,522 (-1.4%) Payment of Exercise Price
    Chief Operating Officer
    Nov 14, 2024 613 $4,855 67,871 (-0.9%) Payment of Exercise Price
    Chief Development Officer
    Nov 14, 2024 402 $3,184 16,961 (-2.4%) Payment of Exercise Price
    President and CEO
    Nov 14, 2024 59,766 $473,347 2,362,747 (-2.5%) Payment of Exercise Price
    Chief Legal Officer
    Nov 14, 2024 184 $1,457 37,941 (-0.5%) Payment of Exercise Price
    Chief Legal Officer
    Oct 17, 2024 558 $4,391 38,125 (-1.5%) Payment of Exercise Price
    Chief Legal Officer
    Oct 1, 2024 284 $1,982 38,683 (-0.7%) Payment of Exercise Price